REGN
REGENERON PHARMACEUTICALS, INC.
Nasdaq: REGN · Tarrytown, NY · Healthcare
$827.72-15.75 (-1.87%)Closed
Market Cap$78.15B
Cash$7.99Bmost recent
Runwayprofitable
P/E (TTM)20.0EPS $41.48
52-Wk Range$552.68 – $852.03
Avg Volume904.5K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$827.72-27.4%
Pipeline
Drug candidates sponsored by REGENERON PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Colchicine (Colcrys®) | Intercritical Gout | Completed | 2012-08past | 1 | |
| Phase 4 | Praluent (Alirocumab) | Hypercholesterolemia | Completed | 2020-03-05past | 1 | |
| Phase 4 | dupilumab | Asthma+8 more | Recruiting | 2027-04-24 | 11 | |
| Phase 4 | Linvoseltamab | Relapsed/Refractory Multiple Myeloma (RRMM)+4 more | Recruiting | 2027-10-11 | 5 | |
| Phase 4 | Pozelimab | CHAPLE Disease+4 more | Recruiting | 2028-10-10 | 7 | |
| Phase 3 | Rilonacept | Gout | Terminated | 2013-06past | 1 | |
| Phase 3 | Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Branch Retinal Vein Occlusion | Completed | 2013-08past | 1 | |
| Phase 3 | Placebo | Gout+1 more | Completed | 2016-01-31past | 2 | |
| Phase 3 | Intravitreal aflibercept injection [IAI] | Nonproliferative Diabetic Retinopathy | Completed | 2018-08-06past | 1 | |
| Phase 3 | Fasinumab | Osteoarthritis of the Knee or Hip | Completed | 2020-12-01past | 1 | |
| Phase 3 | REGN2810/ipi | Non-small Cell Lung Cancer | Terminated | 2021-07-29past | 1 | |
| Phase 2 | aflibercept | Diabetic Macular Edema+3 more | Completed | 2022-08-18past | 2 | |
| Phase 3 | Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | Terminated | 2023-07-12past | 1 | |
| Phase 2 | CMP-001 | Melanoma+3 more | Terminated | 2024-07-22past | 1 | |
| Phase 3 | REGN2810 | Non-small Cell Lung Cancer | Completed | 2025-02-27past | 1 | |
| Phase 3 | Pemetrexed | Carcinoma，Non-Small-Cell Lung+3 more | Completed | 2025-04-18past | 1 | |
| Phase 3 | Cemiplimab | Squamous Cell Carcinoma (SCC)+8 more | Recruiting | 2026-11-02 | 6 | |
| Phase 3 | REGN7508 | Symptomatic Venous Thromboembolism (VTE)+2 more | Recruiting | 2027-05-17 | 3 | |
| Phase 3 | Fianlimab | Melanoma+1 more | Active, not recruiting | 2027-09-28 | 2 | |
| Phase 3 | Odronextamab | Follicular Lymphoma (FL)+1 more | Recruiting | 2028-02-07 | 2 | |
| Phase 2 | REGN475 | Sciatica | Completed | 2010-05past | 1 | |
| Phase 2 | Alirocumab | Hypercholesterolemia | Completed | 2014-06-02past | 2 | |
| Phase 2 | REGN1908-1909 | Cat Allergy+2 more | Completed | 2019-12-21past | 2 | |
| Phase 2 | REGN10933+REGN10987 combination therapy | COVID-19 | Completed | 2021-03-04past | 1 | |
| Phase 2 | evinacumab | Severe Hypertriglyceridemia (sHTG)+1 more | Completed | 2023-02-15past | 2 | |
| Phase 2 | REGN5713 | Allergic Rhinitis+1 more | Completed | 2023-07-31past | 1 | |
| Phase 2 | REGN9933 | Venous Thromboembolism | Completed | 2024-05-27past | 1 | |
| Phase 2 | REGN5381 | Uncontrolled Hypertension | Terminated | 2025-10-15past | 1 | |
| Phase 2 | REGN7544 | Sepsis-Induced Hypotension+2 more | Completed | 2026-05-06past | 3 | |
| Phase 1 | ALN-PNP | Healthy Volunteers+1 more | Recruiting | 2027-08-10 | 2 | |
| Phase 2 | ALN-HSD | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | Recruiting | 2028-04-27 | 1 | |
| Phase 2 | Ubamatamab | Non Small Cell Lung Cancer+3 more | Recruiting | 2030-06-10 | 1 | |
| Phase 1 | ziv-aflibercept | Lymphoma+1 more | Completed | 2007-02past | 1 | |
| Phase 1 | REGN88 | Rheumatoid Arthritis | Completed | 2009-03past | 1 | |
| Phase 1 | REGN475 (SAR164877) | Healthy | Completed | 2009-11past | 1 | |
| Phase 1 | REGN727 | Healthy | Completed | 2010-10past | 1 | |
| Phase 1 | REGN668: Injection Rate 1 | Healthy | Completed | 2012-02past | 1 | |
| Phase 1 | REGN668 | Dermatitis | Completed | 2012-07past | 1 | |
| Phase 1 | REGN1033 (SAR391786) | Healthy Volunteers | Completed | 2013-06past | 1 | |
| Phase 1 | Sarilumab | Rheumatoid Arthritis | Completed | 2015-04past | 1 | |
| Phase 1 | REGN1500 | Metabolic Disorders | Completed | 2015-09past | 1 | |
| Phase 1 | REGN3470-3471-3479 | Healthy Volunteers | Completed | 2017-04-26past | 1 | |
| Phase 1 | REGN1033 | Healthy Volunteers | Completed | 2019-04-30past | 1 | |
| Phase 1 | REGN6490 | Healthy Volunteer | Terminated | 2021-06-01past | 1 | |
| Phase 1 | REGN10933+REGN10987 | Healthy+1 more | Completed | 2021-11-22past | 1 | |
| Phase 1 | Casirivimab+Imdevimab | Healthy+1 more | Completed | 2022-06-03past | 1 | |
| Phase 1 | REGN14284 | Healthy | Completed | 2023-05-30past | 1 | |
| Phase 1 | REGN7999 | Healthy | Completed | 2023-08-29past | 1 | |
| Phase 1 | REGN3767 | Malignancies | Completed | 2024-04-02past | 1 | |
| Phase 1 | REGN7508 (IV) | Healthy Volunteer | Completed | 2024-09-17past | 1 | |
| Phase 1 | REGN7257 | Severe Aplastic Anemia (SAA) | Terminated | 2024-10-17past | 1 | |
| Phase 1 | Aspirin | Healthy Volunteers | Completed | 2025-04-07past | 1 | |
| Phase 1 | Odronextamab multiple dose levels | Non-Hodgkin Lymphoma+1 more | Completed | 2025-08-21past | 1 | |
| Phase 1 | Garetosmab | Obesity+1 more | Withdrawn | 2026-06-08past | 2 | |
| Phase 1 | 89Zr˗DFO˗REGN5054 | Advanced Solid Tumor+1 more | Recruiting | 2027-01-06 | 1 | |
| N/A | ALIROCUMAB SAR236553 (REGN727) | Hypercholesterolemia | Terminated | 2020-09-04past | 1 | |
| N/A | Unnamed | Relapsed/Refractory Follicular Lymphoma | Completed | 2023-10-05past | 1 | |
| N/A | DUPIXENT® | Asthma | Completed | 2026-04-27past | 1 | |
| N/A | Unnamed | Retinopathy of Prematurity | Active, not recruiting | 2026-11-05 | 1 | |
| N/A | Noninterventional | Chronic Kidney Disease (CKD) | Recruiting | 2027-06-14 | 1 | |
| N/A | Vonsetamig | Plasma Cell Mediated+1 more | Available | — | 1 | |
| N/A | REGN5458 | Multiple Myeloma | Approved For Marketing | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.